Literature DB >> 16863784

Efficacy of therapeutic angiogenesis by intramyocardial injection of pCK-VEGF165 in pigs.

Jae-Sung Choi1, Ki-Bong Kim, Woong Han, Dong Sik Kim, Jin Sik Park, Jong Jin Lee, Dong Soo Lee.   

Abstract

BACKGROUND: Intramyocardial injection of vascular endothelial growth factor (VEGF) plasmid DNA was studied to demonstrate improvement of regional myocardial function.
METHODS: Twenty-one pigs that had undergone ligation of the left anterior descending coronary artery were randomly allocated to one of two treatments: intramyocardial injection of pCK-VEGF165 (VEGF group) or pCK-Null (control group) into the ischemic border zone. Electrocardiogram-gated single-photon emission computed tomography was performed 30 and 60 days after the coronary ligation. Segmental variables of perfusion and function were automatically quantified using a 20-segment model. In the segmental analysis, 119 segments were selected for analysis (71 segments in the VEGF group; 48 segments in the control group). Histologic analysis was also performed in the myocardial tissue of the ischemic border zone.
RESULTS: At day 30, there were no significant differences in segmental perfusion, wall thickening, and wall motion between the two groups. In the VEGF group, all variables of perfusion, wall thickening, and wall motion were significantly improved at day 60 compared with those at day 30 (p < 0.05), while there were no differences in the control group. At day 60, perfusion (p = 0.018), wall motion (p = 0.004), and wall thickening (p = 0.068) of the VEGF group were improved compared with those of the control group. Histologic analysis showed that microcapillary density was significantly higher in the VEGF group than the control group (p < 0.001).
CONCLUSIONS: Intramyocardial injection of pCK-VEGF165 significantly augmented neoangiogenesis in the ischemic area and improved regional myocardial function as well as myocardial perfusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16863784     DOI: 10.1016/j.athoracsur.2006.03.028

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  9 in total

Review 1.  Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology.

Authors:  Andrea Caporali; Magnus Bäck; Mat J Daemen; Imo E Hoefer; Elizabeth A Jones; Esther Lutgens; Christian M Matter; Marie-Luce Bochaton-Piallat; Arndt F Siekmann; Judith C Sluimer; Sabine Steffens; José Tuñón; Cecile Vindis; Jolanda J Wentzel; Seppo Ylä-Herttuala; Paul C Evans
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

Review 2.  Gene targeting in ischemic heart disease and failure: translational and clinical studies.

Authors:  Shaina R Eckhouse; Jeffrey A Jones; Francis G Spinale
Journal:  Biochem Pharmacol       Date:  2012-08-28       Impact factor: 5.858

3.  Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model.

Authors:  Shao-ping Nie; Xiao Wang; Shi-bin Qiao; Qiu-tang Zeng; Ju-quan Jiang; Xiao-qing Liu; Xiang-ming Zhu; Guo-xiang Cao; Chang-sheng Ma
Journal:  J Zhejiang Univ Sci B       Date:  2010-12       Impact factor: 3.066

Review 4.  Gene therapy for ischemic heart disease.

Authors:  Madhav Lavu; Susheel Gundewar; David J Lefer
Journal:  J Mol Cell Cardiol       Date:  2010-06-26       Impact factor: 5.000

5.  Evaluation of biolistic gene transfer methods in vivo using non-invasive bioluminescent imaging techniques.

Authors:  Jixiang Xia; Angela Martinez; Henry Daniell; Steven N Ebert
Journal:  BMC Biotechnol       Date:  2011-06-02       Impact factor: 2.563

Review 6.  ETV2/ER71 Transcription Factor as a Therapeutic Vehicle for Cardiovascular Disease.

Authors:  Dong Hun Lee; Tae Min Kim; Joo Kyung Kim; Changwon Park
Journal:  Theranostics       Date:  2019-08-09       Impact factor: 11.556

7.  In vivo transduction of ETV2 improves cardiac function and induces vascular regeneration following myocardial infarction.

Authors:  Sunghun Lee; Dong Hun Lee; Bong-Woo Park; Riyoun Kim; Anh Duc Hoang; Sang-Keun Woo; Wenjun Xiong; Yong Jin Lee; Kiwon Ban; Hun-Jun Park
Journal:  Exp Mol Med       Date:  2019-02-12       Impact factor: 8.718

8.  Microneedle-mediated gene delivery for the treatment of ischemic myocardial disease.

Authors:  Hongpeng Shi; Tong Xue; Yang Yang; Chenyu Jiang; Shixing Huang; Qi Yang; Dong Lei; Zhengwei You; Tuo Jin; Fei Wu; Qiang Zhao; Xiaofeng Ye
Journal:  Sci Adv       Date:  2020-06-17       Impact factor: 14.136

Review 9.  Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success.

Authors:  Galina Dragneva; Petra Korpisalo; Seppo Ylä-Herttuala
Journal:  Dis Model Mech       Date:  2013-02-08       Impact factor: 5.758

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.